Top Medical News
Roshini Claire Anthony, 13 Nov 2018

The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.

Pank Jit Sin, 13 Nov 2018
Even as the medical fraternity moves towards evidence-based practices, our society continues to place their trust in complementary and alternative medicine (CAM). 
Stephen Padilla, 12 Nov 2018
Close monitoring is necessary in chronic hepatitis B (CHB) gravidas with high viraemia (>6 log10 IU/mL), suggests a recent study, adding that extended antiviral therapy is recommended to mothers whose baseline viraemia is >7 log10 IU/mL for higher serological response.
10 Nov 2018
A longer duration of lactation appears to lower the risk of developing nonalcoholic fatty liver disease (NAFLD), according to a recent US study.
Audrey Abella, 09 Nov 2018
The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.
06 Nov 2018
A web-based intervention yields similar weight-loss benefits for nonalcoholic fatty liver disease (NAFLD) patients as a traditional group-based intervention, a recent study has found.
Saras Ramiya, 30 Oct 2018
A systematic review conducted by researchers at the Kirby Institute shows 9-in-10 people who inject drugs have been cured of hepatitis C with direct-acting antiviral (DAA) therapy.
Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
Conference Reports
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Roshini Claire Anthony, 19 Feb 2018

Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.

Jackey Suen, 25 Oct 2017

Eradication of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is becoming achievable, although much work still has to be done, says an expert.

Jackey Suen, 24 Oct 2017

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

04 Oct 2017
Slideshow: Highlights from the Asia Pacific Digestive Week 2017 (APDW 2017)
Naomi Rodrig, 03 Oct 2017

An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.

Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download